Xiao Shelley Hu
About Xiao Shelley Hu
Xiao Shelley Hu serves as the Vice President and Head of DMPK and Clinical Pharmacology at Wave Life Sciences, where she has worked since 2022. With extensive experience in clinical study design and pharmacometrics, she has held various roles at notable companies including Biogen Idec and Akebia Therapeutics.
Current Role at Wave Life Sciences
Xiao Shelley Hu serves as the Vice President and Head of DMPK and Clinical Pharmacology at Wave Life Sciences. She has held this position since 2022. In addition to her leadership role, she is the DMD53 Program Lead, a position she has maintained since 2021. Her responsibilities include overseeing the design and interpretation of clinical study designs and regulatory submissions, as well as providing guidance on pharmacometrics.
Previous Experience at Biogen Idec
Prior to her current role, Xiao Shelley Hu worked at Biogen Idec for a total of seven years. She began as a Scientist II in 2007, advancing to Senior Scientist from 2010 to 2012, and then to Associate Director from 2012 to 2017. During her tenure, she gained extensive experience in pharmacology and contributed to various therapeutic areas.
Experience at Akebia Therapeutics
Xiao Shelley Hu worked at Akebia Therapeutics as a Director for one year, from 2017 to 2018. In this role, she continued to develop her expertise in clinical pharmacology and contributed to the company's research initiatives.
Educational Background
Xiao Shelley Hu studied at multiple institutions, including the Chinese Academy of Sciences, The Ohio State University, and BMU. Her educational background has provided her with a strong foundation in pharmacology and related fields, contributing to her professional expertise.
Expertise in Clinical Pharmacology
Xiao Shelley Hu possesses advanced skills in pharmacometrics and has expertise in oligonucleotides, small and large molecules across various therapeutic areas, including nephrology, neurology, immunology, oncology, and pulmonary diseases. She has experience in designing and reporting pre-clinical pharmacology studies and demonstrates advanced modeling and simulation skills using software such as R, NONMEM, WinBUGS, and STAN.